Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase 11 study in non-chemotherapy-pretreated patients
1998

Docetaxel in Metastatic Urothelial Cancer

Sample size: 30 publication Evidence: moderate

Author Information

Author(s): R de Wit, WHJ Kruit, G Stoter, M de Boer, J Kerger, J Verweij

Primary Institution: Rotterdam Cancer Institute and University Hospital

Hypothesis

Is docetaxel an effective treatment for metastatic urothelial cancer in non-chemotherapy-pretreated patients?

Conclusion

Docetaxel is an effective agent in treating metastatic urothelial cell cancer, with a notable response rate.

Supporting Evidence

  • Four patients achieved a complete response and five a partial response.
  • The overall response rate was 31%.
  • The median duration of response was 6 months.
  • Toxic effects mainly consisted of neutropenia, which rarely caused complications.

Takeaway

Doctors tested a medicine called docetaxel on patients with a type of cancer that had spread, and it helped some of them get better.

Methodology

Patients with metastatic urothelial cancer received docetaxel 100 mg/m² every 3 weeks, and their responses were evaluated.

Limitations

The study had a small sample size and was limited to non-chemotherapy-pretreated patients.

Participant Demographics

Median age was 61 years, with a range of 45-72 years; 25 men and 5 women participated.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication